Ameriprise
NRIX icon

Ameriprise’s Nurix Therapeutics NRIX Stock Holding History

Ameriprise’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$958K Sell
61,825
-62,924
-50% -$1.04M ﹤0.01% 3316
2025
Q4 		$2.37M Buy
124,749
+20,116
+19% +$289K ﹤0.01% 2913
2025
Q3 		$967K Buy
104,633
+62,447
+148% +$648K ﹤0.01% 3382
2025
Q2 		$480K Buy
42,186
+11,500
+37% +$124K ﹤0.01% 3543
2025
Q1 		$365K Sell
30,686
-1,466
-5% -$24.5K ﹤0.01% 3613
2024
Q4 		$606K Buy
32,152
+16,921
+111% +$388K ﹤0.01% 3450
2024
Q3 		$342K Sell
15,231
-31,573
-67% -$715K ﹤0.01% 3604
2024
Q2 		$977K Sell
46,804
-59,060
-56% -$920K ﹤0.01% 3169
2024
Q1 		$1.56M Sell
105,864
-4,848
-4% -$52.1K ﹤0.01% 2986
2023
Q4 		$1.14M Buy
110,712
+50,394
+84% +$345K ﹤0.01% 3132
2023
Q3 		$474K Buy
+60,318
New +$551K ﹤0.01% 3433
2023
Q2 		– Sell
-40,649
Closed -$361K – 3975
2023
Q1 		$361K Buy
40,649
+17,949
+79% +$187K ﹤0.01% 3546
2022
Q4 		$249K Buy
+22,700
New +$274K ﹤0.01% 3654
2021
Q3 		– Sell
-224,686
Closed -$5.96M – 3916
2021
Q2 		$5.96M Buy
224,686
+5,065
+2% +$149K ﹤0.01% 2329
2021
Q1 		$6.83M Buy
219,621
+90,821
+71% +$3.44M ﹤0.01% 2183
2020
Q4 		$4.24M Sell
128,800
-126,448
-50% -$4.19M ﹤0.01% 2383
2020
Q3 		$8.91M Buy
+255,248
New +$6.43M ﹤0.01% 1637

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Ameriprise's NRIX Position: Q1 2026 in Review

Ameriprise reduced its Nurix Therapeutics (NRIX) stake by 50% in Q1 2026, selling an estimated $1.04M and leaving 61,825 shares worth $958K. The position accounts for ﹤0.01% of the portfolio, ranked #3316.

Ameriprise first reported a position in NRIX in Q3 2020 and has held it in 17 quarters since. The position peaked at $8.91M in Q3 2020. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Ameriprise held 61,825 shares of Nurix Therapeutics worth $958K as of Q1 2026.
  • Ameriprise sold 62,924 Nurix Therapeutics shares in Q1 2026, an estimated $1.04M.
  • Nurix Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3316 holding.
  • Ameriprise first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 17 quarters since.
  • Ameriprise's Nurix Therapeutics position peaked at $8.91M in Q3 2020.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.